iBio, Inc. Enters into Common Stock Purchase Agreement for Up to $16.0 Million with Lincoln Park Capital

Read Press Release

Latest Financial Results

Q3 2017

Quarterly Results

Mar 31, 2017
Further recent Filings may be viewed in SEC Filings.

Stock Information

iBio Inc. NYSE American: IBIO
Price Loading...
Change Loading...
Market Cap Loading...
Volume Loading...

Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

View Profile